Sarepta is facing a number of issues currently, including platform-level safety concerns, management credibility issues, etc.

After deaths and FDA setbacks, Sarepta abandoned LGMD gene therapy, leaving families desperate and patients without ...

Rocket’s relatively quick reprieve is good news for the stock, and suggests that the FDA remains actively supportive of gene ...

Citi said on Wednesday that the U.S. Food and Drug Administration may take a “more comprehensive look” at the level of ...

Sarepta Therapeutics has provided additional safety data on its gene therapy Elevidys as a Duchenne muscular dystrophy ...

The debt refinancing follows the firm's recent trouble with the FDA and efforts to refocus its pipeline priorities, preserve resources, and meet financial obligations.

Kriya is advancing a host of gene therapies for a wide variety of chronic diseases, including geographic atrophy, trigeminal ...

A securities class-action lawsuit is underway against Sarepta Therapeutics (NASDAQ: SRPT) , triggered by a series of safety concerns and regulatory setbacks for its gene therapy, ELEVIDYS. The lawsuit ...

The FDA’s shift on Elevidys sends a message: boldness, scientific rigor and urgency are essential in confronting rare ...

A refinancing deal will delay the maturity of $700 million in debt until 2030, allowing the company to “fully fund” its ...

Gene therapy biotech Kriya Therapeutics has secured $313 million in a new series fundraise. | Gene therapy biotech Kriya ...

The drug, based on Nobel Prize-winning gene-editing technology CRISPR-Cas9, reaches the liver cells and splices out the ...